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lysis catheter-related bacteremia by Leclercia
adecarboxylata without catheter removal: re-
port of two cases
Leclercia adecarboxylata is a motile, aerobic, Gram-negative
bacillus, previously known as enteric group 41 or Escherichia
adecarboxylata.1 L. adecarboxylata strains are rarely iso-
lated from clinical specimens of hospitalized patients and its
actual relevance is not well established. Few cases of bac-
teremia in subjects with underlying medical conditions have
been reported.1—4 Catheter-related infection due to L. ade-
carboxylata represents an unusual complication of long-
term, tunneled central venous catheters placed for total
parenteral nutrition1 or chemotherapy.5 There are no pre-
vious reports of hemodialysis catheter-related bacteremia
caused by L. adecarboxylata and successfully managed with
catheter salvage. We report below the successful manage-
ment of two such cases.
The first case is that of an 81-year-old male with end-stage
renal disease (ESRD) secondary to diabetes mellitus, who was
diagnosed with renal cell adenocarcinoma and underwent
radical nephrectomy in 1999. Since 2005 the patient has
undergone hemodialysis (HD) 3 times weekly through a tun-
neled central catheter in the right subclavian vein. In June
2006 he was admitted to the hospital because of fever
starting a few hours after the HD session. On physical exam-
ination, he had a temperature of 38 8C and his blood pressure
was 170/90mmHg. There was no evidence of inflammation at
the insertion site. His white blood cell (WBC) count was
10.5  109/l (91% neutrophils). He received empirical treat-
ment with IV vancomycin and gentamicin. Blood cultures
obtained from the central catheter and by peripheral veni-
puncture yielded pure growth of L. adecarboxylata in four
sets. Identification and in vitro susceptibility testing were
performed using the WIDER System (Soria Melguizo, S.A.,
Madrid, Spain) and were confirmed by API 20E (bioMe´rieux,
Marcy l´Etoile, France). The organism was susceptible to all
antimicrobials tested, with the exception of fosfomycin. The
catheter was locked daily with ciprofloxacin at a concentra-
tion of 2 mg/ml added to sodium heparin (20 IU/ml), and a
15-day course of IV ceftriaxone (2 g every 24 h) was com-
pleted. New blood cultures were sterile. The patient was
discharged, and he remains catheter infection-free after a 2-
year follow-up. HD was subsequently continued through the
pre-existing catheter.1201-9712/$36.00 # 2009 International Society for Infectious Diseases.
doi:10.1016/j.ijid.2009.01.010The second case is that of a 72-year-old male who under-
went a renal transplant in August 2005 for ESRD secondary to
hypertension. HD was reinitiated in September 2006 because
of allograft failure. He had also received an orthotopic heart
transplant in 1991 and was on immunosuppressive therapy
with prednisone, mycophenolate mofetil, and rapamycin. A
tunneled left subclavian vein catheter was placed in April
2008. Four months later the patient presented with a tem-
perature of 38.6 8C and sweating. He remained hemodyna-
mically stable with no abnormalities on physical
examination. There were no signs of inflammation at the
insertion site. His WBC count was slightly elevated
(11.3  109/l with 89% neutrophils). Empirical antibiother-
apy was initiated with IV meropenem, gentamicin and van-
comycin. Three of six sets of blood cultures obtained from the
central line and by peripheral venipuncture were positive for
a Gram-negative bacillus, subsequently identified as L. ade-
carboxylata. Pantoea agglomerans was simultaneously iso-
lated in one of the sets. Identification and susceptibility
testing were performed by the WIDER System and confirmed
by API 20E. Both organisms were susceptible to all antimi-
crobials tested. Antibiotic lock therapy using gentamicin (at a
concentration of 2 mg/ml) and sodium heparin (20 IU/ml)
was performed once daily. Following a 15-day course of IV
meropenem (500 mg every 24 h), the patient was discharged.
Subsequent blood cultures were negative, and he showed
complete recovery after a 2-month follow-up period. HD was
continued through the pre-existing catheter.
L. adecarboxylata is an uncommon pathogen, most often
isolated from the polymicrobial post-traumatic flora of
wound infections in previously healthy patients.1,6,7 Some
authors have suggested that infections due to L. adecarbox-
ylata alone, and particularly those determined by blood
culture, are probably limited to subjects with some degree
of immunosuppression,2,3,6 such as those with ESRD requiring
renal replacement therapy. The presence of L. adecarbox-
ylata in the peritoneal fluid of patients undergoing peritoneal
dialysis is quite exceptional.8,9 However, tunneled hemodia-
lysis catheter-related bacteremia due to this organism has
not been previously reported. No controlled studies have
addressed whether tunneled central catheters must be
removed for the treatment of bloodstream infections caused
by Gram-negative bacilli. An attempt at catheter salvage
may be justified under certain circumstances, and successful
evolution of central catheter-related, Gram-negative bac-
teremia has been demonstrated after this therapeuticPublished by Elsevier Ltd. All rights reserved.
e518 Letter to the Editorapproach, especially in pediatric patients.10 The experience
presented herein, albeit limited, suggests that tunneled
catheter-related bacteremia due to L. adecarboxylata in
patients undergoing HD can be successfully managed without
the necessity of catheter removal.
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